OXFORD, UK, January 27th, 2015.
PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015.
The University of Brighton plans to open an innovative, high-quality centre for higher education in Horsham that will give a major boost to jobs, skills and business opportunities in the Gatwick Diamond area. The university estimates the centre could create an estimated 2,250 new jobs and bring £1.7bn of investment to the region over 10 years, and provide around 3,500 places forstudents.
PharmaVentures was appointed by Novartis as exclusive advisors on the sale of its Horsham site based in the UK in April 2014.
Fintan Walton, Chief Executive, PharmaVentures, Ltd said: “We are delighted that our client Novartis has entered into exclusive negotiations on the potential sale of the Horsham site to University of Brighton. This would have a huge positive impact on the region and provides a positive legacy for Novartis too “.
Nigel Borshell, Vice President, who led the advisory team at PharmaVentures added:“This potential sale will be an important land mark deal with respect to the future use of former manufacturing and R&D sites.”
For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, pharma mergers, acquisitions, divestments and joint venture activities for companies.